吉西他滨联合奈达铂或顺铂方案治疗非小细胞肺癌的临床研究  

Clinical study on gemcitabine combined with nedaplatin or cisplatin in the treatment of advanced non-small cell lung cancer

作　　者：李劲松[1] 韩亮[1] 孙三元[1] 袁保兰[1] 魏卫[1] 

机构地区：[1]徐州市中心医院肿瘤内科,江苏徐州221009

出　　处：《现代肿瘤医学》2012年第10期2079-2081,共3页Journal of Modern Oncology

摘　　要：目的:对比分析吉西他滨联合奈达铂化疗方案和联合顺铂化疗方案分别治疗晚期非小细胞肺癌的疗效及毒性反应。方法:56例晚期患者随机分为奈达铂(NDP)组29例和顺铂(DDP)组27例,两组病人的临床基本特征无显著差异,每例均保证至少进行两个周期的化疗。化疗两个周期后2-3周评价临床疗效。结果:NDP组的治疗有效率为44.8%,与DDP组(40.7%)比较差异无统计学意义(P>0.05)。主要的毒副反应为骨髓抑制和消化道反应,两组骨髓抑制发生率差异无统计学意义(P>0.05),但NDP组消化道反应明显轻于DDP组(P<0.05)。绝大多数患者耐受性良好。结论:吉西他滨联合奈达铂方案治疗晚期非小细胞肺癌与联合顺铂方案临床疗效相当,但不良反应较轻,值得进一步推广应用。Objective：To evaluate the therapeutic effect and toxic reaction of gemcitabine（GEM） combined with nedaplatin（NDP） or cisplatin in the treatment of advanced non-small cell lung cancer（NSCLC）.Methods： A total of 56 patients with advanced non-small cell lung cancer were divided into the nedaplatin group（group NDP,n=29） and the cisplatin group（group DDP,n=27）.There was no significant difference of clinical characteristics between two groups.Each case was guaranteed for at least two cycles of chemotherapy.The clinical efficacy was evaluated after 2-3 weeks.Results：The efficacy of group NDP was 44.8% and group DDP was 40.7%.There was no significant difference between two groups（P0.05）.The main toxic and side reaction were bone marrow depression and digestive reaction.There was no significant difference in the incidence of bone marrow depression between two groups.A lower response rate of digestive reaction occurred in group NDP compared to that occurred in group DDP,with a significant difference between the two groups（P0.05）.Most cases showed better tolerance.Conclusion： The effect of combined chemotherapy with nedaplatin is similar as combined with cisplatin for advanced NSCLC,with milder adverse reactions.

关 键 词：奈达铂 顺铂 非小细胞肺癌 化疗 

分 类 号：R734.2[医药卫生—肿瘤]